drugset / Trial / NCT06532396
A Study Evaluating Multiple Ascending Doses of QRL-101 in Healthy Participants
RandomizedParallel-groupDouble-blindTreatment
Summary
QRL-101-03 is a multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of QRL-101 in healthy participants. QRL-101-03 is a follow-on study to QRL-101-01, an ongoing Phase 1, single ascending dose study to determine the safety, tolerability, and PK profile of QRL-101 after a single dose (ClinicalTrials.gov ID: NCT05667779).
Timeline
- Start
- 2024-07-01
- Primary completion
- 2024-12-20
- Completion
- 2024-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QRL-101 | Unknown | — | Oral |
Indications
No indication recorded.